Mineralys Therapeutics, Inc. $MLYS Position Lifted by UBS Group AG

UBS Group AG raised its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 124.9% during the fourth quarter, HoldingsChannel reports. The fund owned 201,280 shares of the company’s stock after acquiring an additional 111,776 shares during the quarter. UBS Group AG’s holdings in Mineralys Therapeutics were worth $7,304,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC boosted its stake in Mineralys Therapeutics by 198.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after acquiring an additional 676 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Mineralys Therapeutics by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock valued at $271,000 after acquiring an additional 702 shares during the last quarter. Velan Capital Investment Management LP boosted its stake in Mineralys Therapeutics by 0.6% during the 3rd quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company’s stock valued at $6,659,000 after acquiring an additional 1,000 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Mineralys Therapeutics by 11.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,896 shares of the company’s stock valued at $468,000 after acquiring an additional 1,275 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Mineralys Therapeutics by 50.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,846 shares of the company’s stock valued at $140,000 after acquiring an additional 1,283 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on MLYS. Jefferies Financial Group reiterated a “hold” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research note on Friday, March 13th. HC Wainwright set a $56.00 price objective on shares of Mineralys Therapeutics and gave the company a “buy” rating in a research note on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Bank of America increased their price objective on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, Director Daphne Karydas sold 3,000 shares of the stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $25.00, for a total transaction of $75,000.00. Following the sale, the director directly owned 6,200 shares of the company’s stock, valued at approximately $155,000. This represents a 32.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Malcom Rodman sold 14,056 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $28.58, for a total transaction of $401,720.48. Following the sale, the insider directly owned 63,443 shares in the company, valued at $1,813,200.94. This trade represents a 18.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 161,874 shares of company stock valued at $4,342,194 over the last three months. 18.94% of the stock is currently owned by company insiders.

Mineralys Therapeutics Stock Performance

Shares of NASDAQ:MLYS opened at $26.39 on Tuesday. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -12.87 and a beta of 0.49. Mineralys Therapeutics, Inc. has a 1-year low of $12.59 and a 1-year high of $47.65. The company’s fifty day moving average is $27.06 and its two-hundred day moving average is $32.47.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04. Sell-side analysts expect that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.